Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Saved in:
| Title: | Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. |
|---|---|
| Authors: | Kim WR; Stanford University School of Medicine, Stanford, CA, USA., Telep LE; Gilead Sciences Inc., Foster City, CA, USA., Jump B; Gilead Sciences Inc., Foster City, CA, USA., Lu M; Henry Ford Health System, Detroit, MI, USA., Ramroth H; Gilead Sciences Inc., Foster City, CA, USA., Flaherty J; Gilead Sciences Inc., Foster City, CA, USA., Gaggar A; Gilead Sciences Inc., Foster City, CA, USA., Chokkalingam AP; Gilead Sciences Inc., Foster City, CA, USA., Gordon SC; Henry Ford Health System, Detroit, MI, USA. |
| Source: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Apr; Vol. 55 (7), pp. 828-835. Date of Electronic Publication: 2022 Feb 08. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2036 |
|---|---|
| DOI: | 10.1111/apt.16786 |
